ChloroquineV1, Istex, Corpus, bibRecord, 000307

Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression

Identifieur interne : 000307 ( Istex/Corpus ); précédent : 000306; suivant : 000308

Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression

Auteurs : C. Saintes ; M. Saint-Jean ; J. J. Renaut ; B. Dréno ; G. Quéreux

Source :

British Journal of Dermatology [ 0007-0963 ] ; 2015-03.

RBID : ISTEX:61C473CE8CEBF538B3DE7DF774631EB41750743F
Url:

https://api.istex.fr/ark:/67375/WNG-BVR7CV17-K/fulltext.pdf

DOI: 10.1111/bjd.13337

Links to Exploration step

ISTEX:61C473CE8CEBF538B3DE7DF774631EB41750743F

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression</title>
<author><name sortKey="Saintes, C" sort="Saintes, C" uniqKey="Saintes C" first="C." last="Saintes">C. Saintes</name>
<affiliation><mods:affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Saint Ean, M" sort="Saint Ean, M" uniqKey="Saint Ean M" first="M." last="Saint-Jean">M. Saint-Jean</name>
<affiliation><mods:affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Renaut, J J" sort="Renaut, J J" uniqKey="Renaut J" first="J. J." last="Renaut">J. J. Renaut</name>
<affiliation><mods:affiliation>Histopathology Institute, 55 Rue de l'Amiral du Chaffault, 44100, Nantes, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B." last="Dréno">B. Dréno</name>
<affiliation><mods:affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Correspondence: Brigitte Dréno.E‐mail:</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: brigitte.dreno@wanadoo.fr</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Quereux, G" sort="Quereux, G" uniqKey="Quereux G" first="G." last="Quéreux">G. Quéreux</name>
<affiliation><mods:affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:61C473CE8CEBF538B3DE7DF774631EB41750743F</idno>
<date when="2015" year="2015">2015</date>
<idno type="doi">10.1111/bjd.13337</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-BVR7CV17-K/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000307</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000307</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression</title>
<author><name sortKey="Saintes, C" sort="Saintes, C" uniqKey="Saintes C" first="C." last="Saintes">C. Saintes</name>
<affiliation><mods:affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Saint Ean, M" sort="Saint Ean, M" uniqKey="Saint Ean M" first="M." last="Saint-Jean">M. Saint-Jean</name>
<affiliation><mods:affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Renaut, J J" sort="Renaut, J J" uniqKey="Renaut J" first="J. J." last="Renaut">J. J. Renaut</name>
<affiliation><mods:affiliation>Histopathology Institute, 55 Rue de l'Amiral du Chaffault, 44100, Nantes, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B." last="Dréno">B. Dréno</name>
<affiliation><mods:affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Correspondence: Brigitte Dréno.E‐mail:</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: brigitte.dreno@wanadoo.fr</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Quereux, G" sort="Quereux, G" uniqKey="Quereux G" first="G." last="Quéreux">G. Quéreux</name>
<affiliation><mods:affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">British Journal of Dermatology</title>
<title level="j" type="alt">BRITISH JOURNAL OF DERMATOLOGY</title>
<idno type="ISSN">0007-0963</idno>
<idno type="eISSN">1365-2133</idno>
<imprint><biblScope unit="vol">172</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="819">819</biblScope>
<biblScope unit="page" to="821">821</biblScope>
<biblScope unit="page-count">2</biblScope>
<date type="published" when="2015-03">2015-03</date>
</imprint>
<idno type="ISSN">0007-0963</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0007-0963</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
</TEI>
<istex><corpusName>wiley</corpusName>
<keywords><teeft><json:string>cutaneous</json:string>
<json:string>clin</json:string>
<json:string>vedotin</json:string>
<json:string>brentuximab vedotin</json:string>
<json:string>migrans</json:string>
<json:string>brentuximab</json:string>
<json:string>larva</json:string>
<json:string>dermatol</json:string>
<json:string>cutaneous larva migrans</json:string>
<json:string>lymphoma</json:string>
<json:string>hrclm</json:string>
<json:string>anaplastic</json:string>
<json:string>foreign travel</json:string>
<json:string>tumour</json:string>
<json:string>dermatology</json:string>
<json:string>dermatologist</json:string>
<json:string>autochthonous</json:string>
<json:string>mswat</json:string>
<json:string>treatment cycle</json:string>
<json:string>erythroderma</json:string>
<json:string>british association</json:string>
<json:string>british journal</json:string>
<json:string>tropical disease</json:string>
<json:string>mswat score</json:string>
<json:string>dear editor</json:string>
<json:string>mycosis fungoides</json:string>
<json:string>photodynamic therapy</json:string>
<json:string>large cell</json:string>
<json:string>pegylated liposomal doxorubicin</json:string>
<json:string>body surface</json:string>
<json:string>clin lymphoma myeloma leuk</json:string>
<json:string>clinical diagnosis</json:string>
<json:string>funding source</json:string>
<json:string>serpiginous edge</json:string>
<json:string>lymphocyte count</json:string>
<json:string>observation show</json:string>
<json:string>conventional treatment</json:string>
<json:string>clin oncol</json:string>
<json:string>cutaneous anaplastic large cell lymphoma</json:string>
<json:string>cutaneous lymphoma</json:string>
<json:string>epidermotropic cutaneous lymphoma</json:string>
<json:string>lesion</json:string>
</teeft>
</keywords>
<author><json:item><name>C. Saintes</name>
<affiliations><json:string>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</json:string>
</affiliations>
</json:item>
<json:item><name>M. Saint‐Jean</name>
<affiliations><json:string>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</json:string>
</affiliations>
</json:item>
<json:item><name>J.J. Renaut</name>
<affiliations><json:string>Histopathology Institute, 55 Rue de l'Amiral du Chaffault, 44100, Nantes, France</json:string>
</affiliations>
</json:item>
<json:item><name>B. Dréno</name>
<affiliations><json:string>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</json:string>
<json:string>Correspondence: Brigitte Dréno.E‐mail:</json:string>
<json:string>E-mail: brigitte.dreno@wanadoo.fr</json:string>
</affiliations>
</json:item>
<json:item><name>G. Quéreux</name>
<affiliations><json:string>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</json:string>
</affiliations>
</json:item>
</author>
<articleId><json:string>BJD13337</json:string>
</articleId>
<arkIstex>ark:/67375/WNG-BVR7CV17-K</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>letter</json:string>
</originalGenre>
<qualityIndicators><score>3.978</score>
<pdfWordCount>1966</pdfWordCount>
<pdfCharCount>12399</pdfCharCount>
<pdfVersion>1.6</pdfVersion>
<pdfPageCount>3</pdfPageCount>
<pdfPageSize>595.276 x 782.362 pts</pdfPageSize>
<pdfWordsPerPage>655</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>true</refBibsNative>
<abstractWordCount>1</abstractWordCount>
<abstractCharCount>0</abstractCharCount>
<keywordCount>0</keywordCount>
</qualityIndicators>
<title>Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression</title>
<genre><json:string>review-article</json:string>
</genre>
<host><title>British Journal of Dermatology</title>
<language><json:string>unknown</json:string>
</language>
<doi><json:string>10.1111/(ISSN)1365-2133</json:string>
</doi>
<issn><json:string>0007-0963</json:string>
</issn>
<eissn><json:string>1365-2133</json:string>
</eissn>
<publisherId><json:string>BJD</json:string>
</publisherId>
<volume>172</volume>
<issue>3</issue>
<pages><first>819</first>
<last>821</last>
<total>2</total>
</pages>
<genre><json:string>journal</json:string>
</genre>
<subject><json:item><value>Correspondence</value>
</json:item>
<json:item><value>CORRESPONDENCE</value>
</json:item>
</subject>
</host>
<ark><json:string>ark:/67375/WNG-BVR7CV17-K</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - dermatology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - dermatology & venereal diseases</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Dermatology</json:string>
</scopus>
</categories>
<publicationDate>2015</publicationDate>
<copyrightDate>2015</copyrightDate>
<doi><json:string>10.1111/bjd.13337</json:string>
</doi>
<id>61C473CE8CEBF538B3DE7DF774631EB41750743F</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-BVR7CV17-K/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-BVR7CV17-K/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-BVR7CV17-K/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher>
<availability><licence>© 2014 British Association of Dermatologists</licence>
</availability>
<date type="published" when="2015-03"></date>
</publicationStmt>
<notesStmt><note type="content-type" subtype="review-article" source="letter" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression</title>
<author xml:id="author-0000"><persName><forename type="first">C.</forename>
<surname>Saintes</surname>
</persName>
<affiliation><orgName type="division">Skin Cancer Unit, Nantes University Hospital</orgName> 
                        <orgName type="institution">INSERM 892</orgName> 
                        <address><street>1 Place Alexis Ricordeau</street> 
                           <postCode>44093</postCode> 
                           <settlement>Nantes Cedex</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">M.</forename>
<surname>Saint‐Jean</surname>
</persName>
<affiliation><orgName type="division">Skin Cancer Unit, Nantes University Hospital</orgName> 
                        <orgName type="institution">INSERM 892</orgName> 
                        <address><street>1 Place Alexis Ricordeau</street> 
                           <postCode>44093</postCode> 
                           <settlement>Nantes Cedex</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">J.J.</forename>
<surname>Renaut</surname>
</persName>
<affiliation><orgName type="institution">Histopathology Institute</orgName> 
                        <address><street>55 Rue de l'Amiral du Chaffault</street> 
                           <postCode>44100</postCode> 
                           <settlement>Nantes</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0003" role="corresp"><persName><forename type="first">B.</forename>
<surname>Dréno</surname>
</persName>
<affiliation><orgName type="division">Skin Cancer Unit, Nantes University Hospital</orgName> 
                        <orgName type="institution">INSERM 892</orgName> 
                        <address><street>1 Place Alexis Ricordeau</street> 
                           <postCode>44093</postCode> 
                           <settlement>Nantes Cedex</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">G.</forename>
<surname>Quéreux</surname>
</persName>
<affiliation><orgName type="division">Skin Cancer Unit, Nantes University Hospital</orgName> 
                        <orgName type="institution">INSERM 892</orgName> 
                        <address><street>1 Place Alexis Ricordeau</street> 
                           <postCode>44093</postCode> 
                           <settlement>Nantes Cedex</settlement> 
                           <country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<idno type="istex">61C473CE8CEBF538B3DE7DF774631EB41750743F</idno>
<idno type="ark">ark:/67375/WNG-BVR7CV17-K</idno>
<idno type="DOI">10.1111/bjd.13337</idno>
<idno type="unit">BJD13337</idno>
<idno type="toTypesetVersion">file:BJD.BJD13337.pdf</idno>
</analytic>
<monogr><title level="j" type="main">British Journal of Dermatology</title>
<title level="j" type="alt">BRITISH JOURNAL OF DERMATOLOGY</title>
<idno type="pISSN">0007-0963</idno>
<idno type="eISSN">1365-2133</idno>
<idno type="book-DOI">10.1111/(ISSN)1365-2133</idno>
<idno type="book-part-DOI">10.1111/bjd.2015.172.issue-3</idno>
<idno type="product">BJD</idno>
<imprint><biblScope unit="vol">172</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="819">819</biblScope>
<biblScope unit="page" to="821">821</biblScope>
<biblScope unit="page-count">2</biblScope>
<date type="published" when="2015-03"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
                        <ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><textClass><keywords rend="articleCategory"><term>Correspondence</term>
</keywords>
<keywords rend="tocHeading1"><term>CORRESPONDENCE</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-BVR7CV17-K/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component type="serialArticle" version="2.0" xml:id="bjd13337" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2133</doi>
<issn type="print">0007-0963</issn>
<issn type="electronic">1365-2133</issn>
<idGroup><id type="product" value="BJD"></id>
</idGroup>
<titleGroup><title sort="BRITISH JOURNAL OF DERMATOLOGY" type="main">British Journal of Dermatology</title>
<title type="short">Br J Dermatol</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="30"><doi origin="wiley">10.1111/bjd.2015.172.issue-3</doi>
<copyright ownership="thirdParty">Copyright © 2015 British Association of Dermatologists</copyright>
<numberingGroup><numbering type="journalVolume" number="172">172</numbering>
<numbering type="journalIssue">3</numbering>
</numberingGroup>
<coverDate startDate="2015-03">March 2015</coverDate>
</publicationMeta>
<publicationMeta level="unit" position="560" status="forIssue" type="letter"><doi>10.1111/bjd.13337</doi>
<idGroup><id type="unit" value="BJD13337"></id>
</idGroup>
<countGroup><count number="2" type="pageTotal"></count>
</countGroup>
<titleGroup><title type="articleCategory">Correspondence</title>
<title type="tocHeading1">CORRESPONDENCE</title>
</titleGroup>
<copyright ownership="thirdParty">© 2014 British Association of Dermatologists</copyright>
<eventGroup><event agent="SPS" date="2014-11-24" type="xmlCreated"></event>
<event type="publishedOnlineAccepted" date="2014-08-12"></event>
<event type="publishedOnlineEarlyUnpaginated" date="2015-01-18"></event>
<event type="firstOnline" date="2015-01-18"></event>
<event type="publishedOnlineFinalForm" date="2015-03-16"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.7.2 mode:FullText" date="2016-01-05"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">819</numbering>
<numbering type="pageLast">821</numbering>
</numberingGroup>
<correspondenceTo><lineatedText><line>Correspondence: Brigitte Dréno.</line>
<line>E‐mail: <email>brigitte.dreno@wanadoo.fr</email>
</line>
</lineatedText>
</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:BJD.BJD13337.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><titleGroup><title type="main">Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable <fc>CD</fc>
30 expression</title>
</titleGroup>
<creators><creator affiliationRef="#bjd13337-aff-0001" creatorRole="author" xml:id="bjd13337-cr-0001"><personName><givenNames>C.</givenNames>
 <familyName>Saintes</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd13337-aff-0001" creatorRole="author" xml:id="bjd13337-cr-0002"><personName><givenNames>M.</givenNames>
 <familyName>Saint‐Jean</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd13337-aff-0002" creatorRole="author" xml:id="bjd13337-cr-0003"><personName><givenNames>J.J.</givenNames>
 <familyName>Renaut</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd13337-aff-0001" corresponding="yes" creatorRole="author" xml:id="bjd13337-cr-0004"><personName><givenNames>B.</givenNames>
 <familyName>Dréno</familyName>
</personName>
</creator>
<creator affiliationRef="#bjd13337-aff-0001" creatorRole="author" xml:id="bjd13337-cr-0005"><personName><givenNames>G.</givenNames>
 <familyName>Quéreux</familyName>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation countryCode="FR" type="organization" xml:id="bjd13337-aff-0001"><orgDiv>Skin Cancer Unit, Nantes University Hospital</orgDiv>
 <orgName>INSERM 892</orgName>
 <address><street>1 Place Alexis Ricordeau</street>
 <postCode>44093</postCode>
 <city>Nantes Cedex</city>
 <country>France</country>
</address>
</affiliation>
<affiliation countryCode="FR" type="organization" xml:id="bjd13337-aff-0002"><orgName>Histopathology Institute</orgName>
 <address><street>55 Rue de l'Amiral du Chaffault</street>
 <postCode>44100</postCode>
 <city>Nantes</city>
 <country>France</country>
</address>
</affiliation>
</affiliationGroup>
</contentMeta>
<noteGroup xml:id="bjd13337-ntgp-0001"><note numbered="no" xml:id="bjd13337-note-0001">Funding sources: none.</note>
<note numbered="no" xml:id="bjd13337-note-0002">Conflicts of interest: none declared.</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression</title>
</titleInfo>
<name type="personal"><namePart type="given">C.</namePart>
<namePart type="family">Saintes</namePart>
<affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M.</namePart>
<namePart type="family">Saint‐Jean</namePart>
<affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J.J.</namePart>
<namePart type="family">Renaut</namePart>
<affiliation>Histopathology Institute, 55 Rue de l'Amiral du Chaffault, 44100, Nantes, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">B.</namePart>
<namePart type="family">Dréno</namePart>
<affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</affiliation>
<affiliation>Correspondence: Brigitte Dréno.E‐mail:</affiliation>
<affiliation>E-mail: brigitte.dreno@wanadoo.fr</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">G.</namePart>
<namePart type="family">Quéreux</namePart>
<affiliation>Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 Place Alexis Ricordeau, 44093, Nantes Cedex, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="review-article" displayLabel="letter" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre>
<originInfo><publisher>Blackwell Publishing Ltd</publisher>
<dateIssued encoding="w3cdtf">2015-03</dateIssued>
<dateCreated encoding="w3cdtf">2014-11-24</dateCreated>
<copyrightDate encoding="w3cdtf">2015</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<relatedItem type="host"><titleInfo><title>British Journal of Dermatology</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Br J Dermatol</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<subject><genre>article-category</genre>
<topic>Correspondence</topic>
<topic>CORRESPONDENCE</topic>
</subject>
<identifier type="ISSN">0007-0963</identifier>
<identifier type="eISSN">1365-2133</identifier>
<identifier type="DOI">10.1111/(ISSN)1365-2133</identifier>
<identifier type="PublisherID">BJD</identifier>
<part><date>2015</date>
<detail type="volume"><caption>vol.</caption>
<number>172</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>3</number>
</detail>
<extent unit="pages"><start>819</start>
<end>821</end>
<total>2</total>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="bjd13337-cit-0001"><titleInfo><title>Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma</title>
</titleInfo>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Younes</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">AK</namePart>
<namePart type="family">Gopal</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">SE</namePart>
<namePart type="family">Smith</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30:2183–9.</note>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>30</number>
</detail>
<extent unit="pages"><start>2183</start>
<end>9</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Clin Oncol</title>
</titleInfo>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>30</number>
</detail>
<extent unit="pages"><start>2183</start>
<end>9</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="bjd13337-cit-0002"><titleInfo><title>Brentuximab vedotin (SGN‐35) in patients with relapsed or refractory systemic anaplastic large‐cell lymphoma: results of a phase II study</title>
</titleInfo>
<name type="personal"><namePart type="given">B</namePart>
<namePart type="family">Pro</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">R</namePart>
<namePart type="family">Advani</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">P</namePart>
<namePart type="family">Brice</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN‐35) in patients with relapsed or refractory systemic anaplastic large‐cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190–6.</note>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>30</number>
</detail>
<extent unit="pages"><start>2190</start>
<end>6</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Clin Oncol</title>
</titleInfo>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>30</number>
</detail>
<extent unit="pages"><start>2190</start>
<end>6</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="bjd13337-cit-0003"><titleInfo><title>A phase II study of SGN‐30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders</title>
</titleInfo>
<name type="personal"><namePart type="given">M</namePart>
<namePart type="family">Duvic</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">SA</namePart>
<namePart type="family">Reddy</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">L</namePart>
<namePart type="family">Pinter‐Brown</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Duvic M, Reddy SA, Pinter‐Brown L et al. A phase II study of SGN‐30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009; 15:6217–24.</note>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>15</number>
</detail>
<extent unit="pages"><start>6217</start>
<end>24</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Clin Cancer Res</title>
</titleInfo>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>15</number>
</detail>
<extent unit="pages"><start>6217</start>
<end>24</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="bjd13337-cit-0004"><titleInfo><title>CD30‐positive cutaneous T‐cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases</title>
</titleInfo>
<name type="personal"><namePart type="given">K</namePart>
<namePart type="family">Mody</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">JS</namePart>
<namePart type="family">Wallace</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">DM</namePart>
<namePart type="family">Stearns</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Mody K, Wallace JS, Stearns DM et al. CD30‐positive cutaneous T‐cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases. Clin Lymphoma Myeloma Leuk 2013; 13:319–23.</note>
<part><date>2013</date>
<detail type="volume"><caption>vol.</caption>
<number>13</number>
</detail>
<extent unit="pages"><start>319</start>
<end>23</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Clin Lymphoma Myeloma Leuk</title>
</titleInfo>
<part><date>2013</date>
<detail type="volume"><caption>vol.</caption>
<number>13</number>
</detail>
<extent unit="pages"><start>319</start>
<end>23</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="bjd13337-cit-0005"><titleInfo><title>Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports</title>
</titleInfo>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Broccoli</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">E</namePart>
<namePart type="family">Derenzini</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">C</namePart>
<namePart type="family">Pellegrini</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Broccoli A, Derenzini E, Pellegrini C et al. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. Clin Lymphoma Myeloma Leuk 2013; 13:493–5.</note>
<part><date>2013</date>
<detail type="volume"><caption>vol.</caption>
<number>13</number>
</detail>
<extent unit="pages"><start>493</start>
<end>5</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Clin Lymphoma Myeloma Leuk</title>
</titleInfo>
<part><date>2013</date>
<detail type="volume"><caption>vol.</caption>
<number>13</number>
</detail>
<extent unit="pages"><start>493</start>
<end>5</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="bjd13337-cit-0006"><titleInfo><title>Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin</title>
</titleInfo>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Desai</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">GH</namePart>
<namePart type="family">Telang</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">AJ</namePart>
<namePart type="family">Olszewski</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Desai A, Telang GH, Olszewski AJ. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. Ann Hematol 2013; 92:567–8.</note>
<part><date>2013</date>
<detail type="volume"><caption>vol.</caption>
<number>92</number>
</detail>
<extent unit="pages"><start>567</start>
<end>8</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Ann Hematol</title>
</titleInfo>
<part><date>2013</date>
<detail type="volume"><caption>vol.</caption>
<number>92</number>
</detail>
<extent unit="pages"><start>567</start>
<end>8</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<identifier type="istex">61C473CE8CEBF538B3DE7DF774631EB41750743F</identifier>
<identifier type="ark">ark:/67375/WNG-BVR7CV17-K</identifier>
<identifier type="DOI">10.1111/bjd.13337</identifier>
<identifier type="ArticleID">BJD13337</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2015 British Association of Dermatologists© 2014 British Association of Dermatologists</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource>
<recordOrigin>Converted from  (version ) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-BVR7CV17-K/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000307 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000307 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:61C473CE8CEBF538B3DE7DF774631EB41750743F
   |texte=   Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression

Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T‐cell lymphomas after treatment failure despite variable CD30 expression

Source :

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri